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Abstract 
Background. Proton pump inhibitors (PPIs) are indicated for a restricted number of clinical 
conditions, and their misuse can lead to several adverse effects. Despite that, the proportion of 
overuse is alarmingly high. Objective. To test the efficacy of a multifaceted strategy in order to 
achieve a significant reduction of new PPI prescriptions at discharge in hospitalized patients. 
Design. Multicenter longitudinal quasi-experimental before-and-after study conducted from July 
1st2014 to June 30th2017.Participants.44,973 admissions in a network of 5 public teaching 
hospitals of the Italian-speaking region of Switzerland. Intervention. Multifaceted strategy 
consisting in a continuous transparent monitoring-benchmarking and in capillary educational 
interventions applied in the internal medicine departments. To confirm the causality of the results 
we monitored the trend of new PPI prescriptions in the, not exposed to the intervention, surgery 
departments of the same hospital network. Main Measures. New PPI prescriptions at hospital 
discharge. Key results. Over the 36 month study period 44,973 patient files were analyzed. At 
admission, comparing internal medicine vs. surgery departments, 44.9% vs. 23.3% of patients were 
already being treated with a PPI. The annual rate of new PPI prescriptions, for internal medicine 
showed a decreasing trend: 19, 19, 18, 16% in years 2014, 2015, 2016, 2017, respectively (p<0.001, 
2014 vs. 2017; p-for-trend<0.001), while an increasing rate was found in the surgery departments in 
the same years: 30, 29, 36, 36%, respectively (p<0.001, 2014 vs. 2017; p-for-trend<0.001). The 
case mix was significantly associated with the probability of new PPI prescriptions in both 
departments (OR1.35, 95% CI 1.26-1.44 for internal medicine and 1.24, 95% CI 1.19-1.30 for 
surgery). Conclusions. The introduction of a multifaceted intervention significantly reduced the 
time trend of PPI prescriptions at hospital discharge in internal medicine departments. Further 
studies are needed to confirm whether the strategy proposed could contribute to optimize the in-
hospital drug prescription behavior in other healthcare settings as well. 
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Background. 
Over and inappropriate use of proton pump inhibitors (PPIs) represent a global healthcare problem 
leading to significant adverse effects and economic consequences worldwide [1,2]. Despite the fact 
that the use of PPIs should be limited to a well-defined spectrum of clinical conditions [3], the rate 
of new prescriptions in in- and outpatients is still very high, reaching a percentage of 
inappropriateness of more than 50% in patients being admitted to hospitals [4,5]. These data are 
even more alarming considering that the prescription of PPIs, as stated above, is linked to several 
potential adverse effects such as infections (Clostridium difficile, colitis) [6], bone fractures (hip 
and spine) [7], hypomagnesaemia and related electrolyte disturbances [8], nutritional deficiencies 
[9], acute and chronic kidney diseases [10,11]  and possibly, ischemic heart disease [12], dementia 
[13]  and gastric carcinoids [14]. 
Many factors could influence the sustained inappropriate use of PPIs, among which the sometimes 
uncritical continuation of primary care physicians’ medications during the hospital stay, as well as 
the chronic renewal of PPI prescriptions after patients’ discharge from the hospitals [15-17].   
In hospitalized patients the initiation of a therapy with PPIs should be limited to specific clinical 
conditions, such as gastritis, gastro-esophageal reflux diseases, gastrointestinal bleeding and stress 
and medication related gastric ulcer prophylaxis [18]. Overuse is however frequent in this setting 
and mainly related to disregard of recommendations and to liberal interpretations of indication in 
the prevention of stress ulcers with potential adverse drug events in a context of minimal expected 
benefit on clinical outcome [18]. 
Several efforts targeted at reducing PPI prescriptions in hospitalized patients have been described; 
e.g. promoting the use of the minimum effective dose and affording different diagnoses or 
treatments in unresponsive patients to PPIs therapy [19]. At the international level the “Choosing 
Wisely” campaign advises physicians not to prescribe medications for stress ulcer prophylaxis to 
medical inpatients unless at high risk for complications [20]. 
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Nevertheless, interventions targeting PPI prescriptions still represent an important public health 
challenge, mostly at the hospital level where the rate of potentially inappropriate prescriptions 
sometimes reaches dramatic levels [21].  
To date, no multifaceted interventions targeted to decrease PPI prescriptions have been evaluated in 
the hospital setting.  
We proposed therefore a strategy based on a multi-level decision-making intervention: 1) 
educational intervention, based on the concept of patient-centred medicine [22], aimed to raise 
awareness about PPIs overtreatment, prescription inappropriateness and side effects; and 2) a 
continuous transparent monitoring system enabling in-hospital healthcare providers to open 
benchmarking and to optimize new PPI prescriptions in a proactive and comprehensive approach.  
Our hypothesis was that a continuous transparent monitoring system combined with an educational 
intervention would lead to a significant reduction of new PPI prescriptions at discharge. 
The primary study objective was hence to obtain a significant decrease in the rate of new PPI 
prescriptions in the internal medicine departments following the implementation of the intervention. 
Secondary study objectives were i) to verify the absence of new prescription reduction in surgery 
departments, where the staff was also exposed to the publication of internal and targeted Choosing 
Wisely recommendations but in the absence of involvement in the open benchmarking and in the 
active educational intervention (controls) ii) to identify factors independently associated with new 
PPI prescriptions. 
 
Materials and Methods 
We conducted a multicenter longitudinal quasi-experimental before and after study from July 1st 
2014 to June 30th 2017 in a network of 5 teaching public hospitals (Ente Ospedaliero Cantonale, 
EOC) of the Italian-speaking part of Switzerland (Flow-Diagram of the Study, Appendix 1). We 
considered in the analysis data of all inpatients admitted in the internal medicine departments 
(intervention group) during the study period, and compared them to all inpatients admitted in the 
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surgery departments (control group). The hospitals involved in the study were 5: H1, H2, H3, H4 
and H5 and all were organized in internal medicine and surgery departments. The internal medicine 
and the surgery departments included respectively the following units: general internal medicine, 
geriatrics, nephrology and general surgery, orthopedic and traumatology, and vascular and thoracic 
surgery. 
Basic demographic data and information on diagnoses and case mix (CM) were collected from the 
electronic patient records of the hospitals. The CM, as relative value assigned to the patients’ Swiss 
Diagnosis-Related Group at hospital discharge, is an indicator of illness severity used to calculate 
hospitals’ reimbursements [23].  
The study was compliant with the “Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) Statement” guidelines [24]. According to Swiss law, studies based solely 
on anonymous secondary data do not require approval from an ethics review board [25]. 
The multifaceted intervention was implemented stepwise over the 36 month study period (Figure 1) 
and was aimed at improving hospitals’ PPI prescriptions by: i) educational interventions based on 
implementation of hospitals’ best-practice guidelines (see Appendix 2 for internal 
recommendations), promoting awareness of the potential prescription inappropriateness and side 
effects of PPIs; and ii) continuous transparent monitoring/benchmarking of new PPI prescriptions.  
The intervention was applied in the internal medicine departments, while the data of the surgery 
departments were used as controls to further evaluate the impact of the strategy. The educational 
intervention included face-to-face feedbacks and meetings and educational outreach visits by local 
opinion leaders. Healthcare providers were sensitized at different levels on the importance of i) 
making wise decisions in PPI prescription (sharing with patients information on risks about the 
medication and on evidence of over- and inappropriate prescriptions); ii) identifying patients in 
which PPIs are not indicated and/or are potentially dangerous; iii) withdrawing PPIs when not, or 
no longer indicated iv) promoting behavior changes by consulting the monitoring/benchmarking 
platform on new PPI prescriptions. The educational intervention was based on multiple components 
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making it a ‘complex educational intervention’ in which the full spectrum was targeted to change 
physicians' behavior.  
 
A. Educational meetings: educational meetings were held repeatedly and capillary in the 
department of the intervention. In each meeting feedback and management guidelines on 
PPI prescriptions were discussed with all healthcare providers involved. The educational 
meetings were conducted by a group of experts composed of at least 2 clinicians (a 
specialist in general internal medicine and a specialist in medical pharmacology), a 
biostatistician and an expert in quality and patient safety. 
B. Educational materials: printed and electronic versions of the internal guidelines, as rapid 
clinical-decision making supports, were distributed in a capillary way; pocket-forms were 
also available (see Appendix 1). The recommendations were based on national and 
international guidelines.  
C. Electronic media communication: healthcare providers of all services of the intervention 
group received email newsletters periodically with key educational messages. 
The continuous transparent monitoring/benchmarking of new PPI prescriptions consisted in a 
centralized, transparent platform (i.e. allowing unrestricted access to data by all health care 
providers involved in the project), called “Reporting Wisely”, able to collect weekly updated data 
about new PPI prescriptions, and to perform variability analysis and benchmarking both internally, 
according to time, for the same hospital by units, services and departments and externally at the 
network level. User friendly continuously updated graphics depicting the results of the monitoring 
were also available for any evaluation by the physicians and nurses of the staff involved in the 
project of the internal medicine departments.  
The primary outcome of the study was to obtain a significant reduction in the rate of new PPI 
prescriptions at hospital discharge. New PPI prescriptions were considered as the presence in the 
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medication list, given to the patient at hospital discharge, of at least one drug belonging to the PPI 
class in a previously naïve patient. 
 
Statistical analysis 
A relative reduction of new PPI prescriptions of 15% was considered as relevant. It was calculated 
that a sample size of 4142 patients was required to test the hypothesis that the intervention was 
efficient in producing a decrease of PPI prescriptions from 20 to 17% (relative reduction of 15%). 
Calculations used a one sided significance of 0.05 and a power of 80%. Power calculations were 
carried out using G*Power (V.3.1.7). 
Baseline characteristics were summarized using the median and the interquartile range or 
frequencies and percentages, as appropriate. Data were analysed into two groups based on the 
hospital department (internal medicine vs. surgery; i.e. intervention vs. non-intervention). 
Comparisons were performed using an independent samples t-test or a Chi-square test, as 
appropriate. Temporal trends of new PPI prescriptions were examined and analyzed by calendar 
quarter, considering the two departments separately. Quarterly and annual rates of new PPI 
prescriptions were calculated and differences were evaluated using the Chi-square test. Changes 
over time in the percentage of new PPI prescriptions were examined using Chi-square tests for 
trends.  
A multivariate regression analysis was performed to identify factors independently associated with 
new PPI prescriptions (dependent variable). Fully adjusted models included fixed effects for years 
(2014, 2015, 2016, and 2017), hospitals (H1, H2, H3, H4, and H5), hospital-year interaction, 
gender, age, and the individual Case Mix. Odds ratios (OR) with 95% confidence intervals (95% 
CI) were calculated. R statistical software (www.r-project.org) was used for data analysis. 
Statistical significance for all outcomes was set at p ≤ 0.05. 
 
Results 
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Overall, 44,973 patient files over the 36 months of the monitoring and intervention period were 
analyzed. Table 1 summarizes the characteristics of the study population in the internal medicine 
and surgery departments. The median age of the study participants was 75 years for internal 
medicine (intervention group) and 67 years for surgery (control group). Most patients were older 
than 65 years in both departments and the Case Mix (CM) was slightly higher in the surgery 
departments (0.80 vs 0.70). At admission, 44.9% of the patients were already taking PPIs in internal 
medicine vs. 23.1% in the surgery departments. The proportion of patients already treated at the 
admission with a PPI among age groups (<65; 65-80 and >80 years) was 31.8, 49.9 and 50.3% in 
the internal medicine: and 12.9, 30.2 and 36.7%. in surgery. At discharge, new PPI prescriptions in 
internal medicine and surgery departments were 18.1 and 32.8%, respectively. New PPI 
prescriptions among age groups (<65; 65-80 and >80 years) for internal medicine and surgery 
departments were 38.4, 36.9 and 24.7% and 53.7, 31.4 and 14.9%, respectively. Admissions for, 
and diagnosis of upper gastrointestinal bleeding during the hospital stay, did not increase 
significantly during the observation (2.0, 1.9, 2.1 and 2.1% in 2014, 2015, 2016 and 2017 
respectively). The time trend of new PPI prescriptions at discharge for each hospital of the network 
by departments showing an important inter- and intra-institutional variability is represented in 
Figure 1 and Figure 2. For the internal medicine department the crude rate of new PPI 
prescriptions decreased over the study period, from 18 (year 2014) to 16% (year 2017) (p <0.001); 
(Figure 1). The annual rate, for the department of internal medicine, also shows a decreasing trend: 
19, 19, 18, and 16% in 2014, 2015, 2016, and 2017, respectively (p for trend <0.001) (Figure 2). 
For the surgery departments, where the intervention was not applied, an increasing yearly trend in 
new PPIs prescriptions was on the contrary found: 30, 29, 36 and 36% in 2014, 2015, 2016 and 
2017, respectively (p<0.001, p for trend <0.001); year 2014 vs. year 2017: 30 vs. 36% (p<0.001).  
In Figure 3 the trends by quarter of new PPIs prescription across the hospital network, by 
department, are shown.  
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In Figure 4 we investigated whether the rate of new PPI prescriptions varied among the different 
age groups over the study period in both departments under analysis. In the internal medicine 
department for the age group < 65 in the years: 2014, 2015, 2016, 2017 the rate of new PPI 
prescriptions were: 22.4, 21.7, 19.1 and 18.5 %, respectively (p for trend 0.015). The difference in 
the rate of new PPI prescriptions in the same age group before vs. after the intervention (years 
2014-2015 vs. 2016-2017) was significant (p 0.013) (Figure 4A). Differences in temporal trends 
among the other age groups were on the contrary non-significant. In the department of surgery, in 
the age group <65 we detected a significant increase in the rate of new PPI prescriptions: 31.7, 30.0, 
36.1 and 41.0% in the years 2014, 2015, 2016 and 2017, respectively (p for trend <0.001) (Figure 
4B). An increasing temporal trend was also found for the age groups 65-80 and >80 years (p<0.001 
for both). 
We used logistic regression to model the probability of receiving a new PPI prescription during 
hospitalization, by department (Table 2). For the internal medicine department the odds ratio of 
having a new PPI prescription decreased significantly with age (OR= 0.99; 95% CI 0.99-1.00; 
p<0.001) and increased with CM (OR =1.33; 95% CI, 1.24-1.43, p<0.001). Gender on the contrary 
did not appear to affect the probability of a new PPI prescription. Compared with 2014 (when the 
monitoring started), the odds of new PPI prescriptions was significantly lower in 2017 (the third 
year of the intervention), with an odds ratio of 0.82 (95% CI, 0.71-0.96; p=0.014). For the 
department of surgery the multivariate analysis revealed that the probability of receiving a new PPI 
prescription was lower for males (OR = 0.86; 95% CI 0.80-0.92; p<0.001) and increased with CM 
(OR 1.24, 95% CI 1.19-1.30; p<0.001.), and over time (for the year 2017 compared with 2014, OR 
= 1.29, 95% CI, 1.14-1.47, p<0.001). 
 
4. Discussion 
We designed and implemented a multifaceted multilevel intervention and evaluated its effectiveness 
in curbing the prescription of proton pump inhibitors in hospitalized patients at discharge.  
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Our intervention resulted in statistically significant reduction over time in PPI prescriptions in the 
internal medicine departments (p for trend 0.02), where the program was applied. Its effectiveness 
was further confirmed analysing the opposite temporal trend of new PPI prescriptions in the surgery 
departments (p for trend <0.001) where targeted actions on the contrary were not applied and where 
the prescription behaviour over time suggests an “epidemic pattern” of continuous growth. The 
magnitude of the relative reduction in PPI prescriptions in the intervention department of about 16% 
(absolute reduction 3%) is not numerically impressive but consistent if the 3 year follow-up is 
considered. Reducing inappropriate PPI prescriptions in the hospital setting represents an important 
public health challenge and is a topic of continuous targeted interventions; as in our case however 
(the surgery department was exposed to the specific Choosing Wisely and internal 
recommendations but not to the capillary educational program and to the prescription 
monitoring/benchmarking), only the use of multifaceted interventions, have until now shown 
consistent and sustained results in influencing medication prescription strategies and poly-pharmacy 
[26,27]. The aim of the study was to analyze and optimize PPI prescriptions at discharge in 
previously untreated patients. The rationale was to stop the epidemic long-term PPI prescription 
wave, by concentrating on one of the key actors of the process; that is to say the hospital care 
givers. The prescriptions limited to the in-hospital stay were however not analyzed. Previous studies 
aimed at ameliorating PPI prescriptions in the hospital setting have been published [28]; the 
efficacy of multifaceted intervention in this setting was, however, not convincingly demonstrated. 
Embracing the principles of the “Choosing Wisely” philosophy based on high value care and shared 
decision making, we targeted a higher level of awareness and “positive” and “negative” guideline 
compliance in the prescription behaviors. Findings from our study indicate that a multilevel strategy 
(transparent monitoring-benchmarking system associated with capillary educational interventions) 
could be a useful way to face the issue of the inadequacy of new PPI prescriptions in hospitalized 
patients. Negative consequences of the restrictive PPI prescription policy were not seen; admissions 
for, and diagnosis of upper gastrointestinal bleeding during the hospital stay, did not increase 
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significantly (2.0, 1.9, 2.1 and 2.1% in 2014, 2015, 2016 and 2017 respectively). Our intervention 
could have been effective due to four key elements: transparent benchmarking, knowledge sharing, 
reflective practice, and supportive-interactive tools. We believe that the intervention here proposed 
on top of the usual strategy based on dispensing recommendations and “positive” and “negative” 
guidelines, significantly contributed to reducing PPI prescriptions, by progressively generating an 
attitudinal change. The possibility of continuously monitoring their own prescriptive behavior and 
comparing it to that of the other institutions involved, could definitely represent a strong stimulus 
encouraging clinicians to undertake immediate actions. As shown in previous studies [29], we also 
demonstrated that the educational outreach based on training healthcare providers to supply high-
value care supported by sensitive data is more effective in generating prescription awareness and 
adaptive behavior than passive guideline dissemination. Overall the strengths of our intervention 
can be summarized in several key points: i) multifaceted structure in the hospital setting (most of 
the previous multifaceted studies on PPI prescription were conducted at the primary care level 
[30,31]); ii) the intervention was carried out over a long period of time (36 months); one of the 
longest observation periods in this field [30,32]; iii) the efficacy of the intervention was assessed on 
a large multicenter population, in a network of internal medicine departments; iv) the educational 
intervention was based on multiple components and unlike other studies several educational 
meetings were held [33,34]; v) most of the previous studies had de-prescription of PPI as the 
primary outcome; while our primary outcome was to contain new prescriptions [35-37]; vi) in our 
study we involved, with motivational letters, general practitioners in the campaign, hoping to curb 
the vicious circle of inappropriate prescriptions.  
We also showed that the Case Mix was significantly associated with the risk of having a new PPI 
prescription in both departments under analysis (OR 1.33; 95% CI 1.24-1.43 internal medicine 
department; OR 1.25, 95% CI 1.19-1.31, surgery department). This could be of interest because 
recently an association between cardiac and metabolic diseases, both significantly impacting the 
CM, and the over-prescription of PPIs was documented [38]. Surprisingly, in our study, in the 
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internal medicine department, age seemed to reduce the probability of receiving new PPI 
prescriptions (OR 0.99; CI 0.99 - 1.00), which is apparently in contrast with our internal 
recommendations, in which age > 65 years is highlighted as one of the risk factors to be considered 
as a trigger for PPI prescription. We believe that this finding could have been related to peculiar 
interconnected and potentially confounding aspects of the study population, mainly related to the 
spectrum of diseases, potentially justifying new or former PPI prescriptions [31-34], and the 
percentage of PPI untreated patients at hospital admission (50% versus 32% in over and under 65 
years respectively in our study), which both vary significantly between age groups. Our study has 
however some limitations that should be acknowledged. The first one is related to the quasi-
experimental design; randomized controlled trials should indeed be used to evaluate the 
effectiveness of interventions. Furthermore, in relation to the study design, we have to acknowledge 
that the intervention group and the surgery departments used as an indirect “control”, differed in the 
characteristics of both patients and providers. The prescription behavior of the surgery departments 
was analyzed to either reinforce or weaken the hypothesis that the improvement targeted in the 
internal medicine department would have been a consequence of the intervention. Comparison 
between groups should be read in the perspective of the global PPI prescription temporal trend. We 
can therefore not definitively prove causation between the implementation of our strategy and the 
outcome. Moreover, we did not assess whether or not the reduction in new PPI prescriptions 
obtained in the departments of internal medicine improved appropriateness and/or translated into a 
better clinical outcome and finally we cannot be sure that the observed reduction in new PPI 
prescriptions will persist over time. The intervention was addressed to clinicians and healthcare 
providers working in a network of teaching hospitals, therefore diversified in terms of age, years of 
practice, and overall with different personal sensibility towards the Choosing Wisely Campaign. 
Thus caution is needed in generalizing the findings to other clinical settings and to other 
populations.  
Further studies are needed to confirm the results and to explore the impact on clinical outcome.  
14 
 
Conclusions 
Over-prescription of PPIs at the hospital level is a big concern worldwide. The initial benchmarking 
at the network level helped us to understand that recommendations and guidelines alone, repeatedly 
proposed in the recent years, would not lead to behaviour changes. Appropriate prescriptions call 
for deliberate judicious treatment strategies based on knowledge of the evidence/guidelines 
(education), awareness of the roots of one’s own prescription behaviour (transparent monitoring and 
benchmarking), motivation (transparent monitoring and benchmarking), and is reinforced by 
encouraging conversations between patients and clinicians on the risks of unnecessary care 
(education). Embracing the philosophy of Choosing Wisely we have built a multifaceted and 
multilevel improvement strategy, supported by supportive-interactive tools helping clinicians to 
build awareness and to change habits. Given the positive findings presented here, we plan to further 
model the intervention components to reinforce even more the physician and patient compliance. 
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Tables and figure Legends 
 
 
Table 1. Characteristics of the study population (44,973 admissions) by departments for the 
study period 2014-2017. 
 
 
 
  
 
 
 
 
 Internal Medicine 
Department 
Surgery 
Department 
Admissions (n.) 26.312 18.661 
H1, n (%)   2.995 (11.4) 1.536 (8.2) 
H2, n (%) 4.975 (18.9) 3.273 (17.5) 
H3, n (%) 6.558 (24.9) 4.545 (24.4) 
H4, n (%) 5.805 (22.1) 4.531(24.3) 
H5, n (%) 5.976 (22.7) 4.776 (25.6) 
Age, years (median, Q1-Q3) 75 (63-83) 67 (50-78) 
Age groups, n (%)   
<65, y 7.200 (27.4) 8.658 (46.4) 
65-80, y 10.107 (38.4) 6.241 (33.4) 
>80, y 9.005 (34.2) 3.762 (20.2) 
Gender, females (%) 13.129 (49.9) 9.630 (51.6) 
Case-mix (median, Q1-Q3) 0.70 (0.51-0.92) 0.80 (0.53 -1.49) 
PPIs admission, n (%) 11.829 (44.9) 4.339 (23.3) 
PPIs discharge, n (%) 13.337 (50.7) 8.534 (45.7) 
New PPI prescriptions, n (%) 2.617 (18.1) 4.696 (32.8) 
New PPI prescriptions by hospital   
H1, (%) 328 (12.5) 546 (11.6) 
H2, (%) 379 (14.5) 487 (10.4) 
H3, (%) 747 (28.5) 1.316 (28.1) 
H4, (%) 481 (18.4) 772 (16.4) 
H5, (%) 682 (26.1) 1.575 (33.5) 
New PPI prescriptions by age groups, 
n (%) 
  
<65, y 1.004 (38.4) 2.524 (53.7) 
65-80, y 967 (36.9) 1.472 (31.4) 
>80, y 646 (24.7) 700(14.9) 
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Table 2. Multivariate analysis of factors associated with receiving a new PPI prescription at 
hospital discharge, by department. 
 
 
 
Abbreviations: OR, odds ratio; CI, confidence interval.  
 
 
                     Internal Medicine Department 
 OR (95% CI) p-value 
Hospitals   
H1 1 [Reference]  
H2 0.56 (0.47 - 0.66)    <0.001 
H3 0.91 (0.78 -1.05)    0.199 
H4 0.57 (0.48 - 0.66)    <0.001 
H5 0. 92 (0.79 - 1.07)    0.254 
Year of the study   
2014 1 [Reference]  
2015 1.01 (0.89 - 1.14)    0.918 
2016 0.92 (0.81 - 1.05)    0.220 
2017 0.82 (0.71 - 0.96)    0.014 
Gender   
Female  1 [Reference]  
Male 0.99 (0.90 - 1.08) 0.783 
Age 0.99 (0.99 - 1.00) <0.001 
Case Mix 1.35 (1.26 -1.44) <0.001 
                       Department of Surgery 
Hospitals   
H1 1 [Reference]  
H2 1.02 (0.77-1.35) 0.899 
H3 1.39 (1.07-1.79) 0.013 
H4 0.69 (0.52-0.91) 0.010 
H5 1.20 (0.92-1.56) 0.176 
Year of the study   
2014 1 [Reference]  
2015 0.95 (0.85 -1.06) 0.327 
2016 1.30 (1.17 - 1.45) <0.001 
2017           1.29 (1.14 - 1.47) <0.001 
Gender   
Female 1 [Reference]  
Male 0.86 (0.80 - 0.92) <0.001 
Age 1.0 (1.0-1.01) 0.696 
Case Mix 1.24 (1.19-1.30) <0.001 
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Figures Titles and Legends 
 
Figure 1: 
Title: 
Rate time trends of new PPI prescriptions in the internal medicine departments where the 
intervention took place. 
Legend: 
Rate of new PPI prescriptions in the internal medicine departments, calculated quarterly. 
Dashed lines represent 95% pointwise confidence intervals. A decreasing temporal trend in 
PPI prescriptions over the study period was found (p for trend <0.001). The temporal pattern 
of the interventions is depicted in the upper part of the figure. 
Figure 2: 
Title: 
Rate time trends of new PPI prescriptions in the surgery departments, where there was no 
intervention. 
 
Legend: 
Rate of new PPI prescriptions in the surgery departments, calculated quarterly. Dashed lines 
represent 95% pointwise confidence intervals. An increasing temporal trend in PPI 
prescriptions over the study period was found (p for trend <0.001).   
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Figure 3 
Title: 
Trends by quarter of new PPI prescriptions throughout the hospital network, by department. 
 
Legend: 
Intra- and inter-hospital variability of new PPI prescriptions during the study period by 
departments. The rate over time is represented for each quarter of the study years. 
 
Figure 4 
Title: 
Rate of new PPI prescriptions within age groups over the study period. 
Legend: 
Panel A. Internal medicine departments: a significant decrease in the rate of new PPI 
prescriptions in the age group < 65 years during the study period was found (p for trend 
0.015). Panel B. Surgery departments: a significant increase in the rate of new PPI 
prescriptions in all age groups over the study period was found (p for trend <0.001). 
 
 
 
 
